يعرض 1 - 18 نتائج من 18 نتيجة بحث عن '"Renad, Alyautdin"', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal

    المصدر: Safety and Risk of Pharmacotherapy; Том 8, № 3 (2020); 160-162 ; Безопасность и риск фармакотерапии; Том 8, № 3 (2020); 160-162 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2020-8-3

    وصف الملف: application/pdf

    Relation: https://www.risksafety.ru/jour/article/view/197/287; Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9; Favalli EG, Caporali R. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Lancet Rheumatol. 2020;2(8):e448–e449. https://doi.org/10.1016/S2665-9913(20)30185-5; Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164. https://doi.org/10.1186/s12967-020-02339-3; Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–8. https://doi.org/10.1016/j.dsx.2020.05.018; Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. https://doi.org/10.1038/s41467-019-13940-6; Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020;383:10.1056/NEJMc2022236#sa5. https://doi.org/10.1056/NEJMc2022236; Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, at al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9; Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18; Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020-4-14. https://doi.org/10.7573/dic.2020-4-14; Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo. 2020;34(3 Suppl):1597–1602. https://doi.org/10.21873/invivo.11949; Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5. https://doi.org/10.1073/pnas.2005615117; Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954; Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3; https://www.risksafety.ru/jour/article/view/197

  5. 5
    Academic Journal
  6. 6
  7. 7
  8. 8
    Academic Journal

    مصطلحات موضوعية: RM Therapeutics. Pharmacology

    وصف الملف: text

    Relation: http://ir.unimas.my/id/eprint/35427/1/AJP181131622403000.pdf; Saiful Bahri, Talip and Marina, Kapitonova and Sergey, Gupalo and Renad, Alyautdin and Ibrahim, Abdel Aziz Ibrahim and Norita, Salim and Azhar, Ahmad and Tin, Moe Nwe and Svetlana, Morokhina (2012) Gastroprotective effect of Berberis vulgaris on ethanol-induced gastric mucosal injury: Histopathological evaluations. Avicenna Journal of Phytomedicine, 11 (3). pp. 1-12. ISSN 2228-7949

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18